Abstract
Peroxiredoxin I (Prx I) is a dual-functional protein that serves as both an antioxidant peroxidase and a molecular chaperone, playing critical roles in cancer development and inflammation. While its peroxidase function is well-studied, the lack of selective inhibitors has hindered research into its chaperone activity. This study identifies the natural product triptolide as a selective inhibitor of Prx I's chaperone function. Triptolide covalently binds to specific cysteine residues (Cys83 and Cys173), triggering the dissociation of high-molecular-weight oligomers necessary for chaperone activity while leaving the dimeric peroxidase form unaffected. Furthermore, celastrol and withaferin A were identified as even more potent inhibitors. These findings provide the first pharmacological tools for dissecting the distinct biological roles of Prx I.
Introduction
Peroxiredoxin I (Prx I) is a "moonlighting" protein with two distinct enzymatic roles. In its low-molecular-weight dimeric form, it acts as a peroxidase to neutralize hydrogen peroxide. Under conditions of oxidative stress, Prx I assembles into high-molecular-weight decamers and larger oligomers that function as molecular chaperones, preventing the aggregation of misfolded proteins.
The challenge in studying Prx I lies in its dual nature; genetic knockdowns eliminate both functions, making it impossible to attribute specific cellular outcomes to one role or the other. While peroxidase inhibitors like adenanthin exist, no selective chaperone inhibitors were previously known. This study sought to fill this gap using chemical proteomics to identify small molecules that could "surgically" inhibit Prx I's chaperone activity.
Methodology and Probe Synthesis
The researchers utilized a chemical biology approach centered on triptolide (TL), a bioactive diterpenoid. To identify its cellular targets, they synthesized two chemical probes: a biotinylated version (Biotin-TL) for affinity purification and a fluorescent version (Cy3-TL) for visualization.
The synthesis of these probes involved a multi-step organic synthesis starting from a dehydroabietic acid derivative, incorporating various linkers to attach the biotin or cyanine 3 moieties without disrupting the core binding scaffold of triptolide.
Target Identification and Validation
Using Biotin-TL in MDCK cell lysates followed by streptavidin pull-downs and MALDI-TOF mass spectrometry, Prx I was identified as the primary covalent target. The binding site was mapped using LC-MS/MS and site-directed mutagenesis, confirming that TL binds covalently to Cys83 and Cys173.
Key Insights: Selective Structural Dissociation
The most significant discovery is the mechanism of selective inhibition. Triptolide's binding to Cys83 and Cys173 disrupts the interfaces required for decamer formation. Size-exclusion chromatography (SEC) and native mass spectrometry revealed that TL treatment causes the large chaperone-active oligomers to dissociate into smaller dimers and tetramers.
Crucially, because the peroxidase activity resides in the dimeric state, TL treatment does not inhibit the antioxidant function. In fact, by promoting the dimeric state, it ensures the peroxidase activity remains intact while specifically shutting down the chaperone function. This functional orthogonality is a rare and powerful feature for a pharmacological tool.
Results and Comparative Potency
Functional assays confirmed the selectivity of the inhibition:
- Chaperone Activity: In a Malate Dehydrogenase (MDH) thermal aggregation assay, TL significantly reduced Prx I's ability to prevent protein clumping.
- Peroxidase Activity: TL showed no inhibitory effect on peroxidase activity even at high concentrations (80 µM), whereas the known peroxidase inhibitor adenanthin showed strong suppression.
- Expanded Inhibitor Discovery: Screening other natural products revealed that celastrol and withaferin A are even more potent than triptolide, exhibiting higher binding occupancy and more effective suppression of MDH aggregation.
Conclusion and Future Directions
This study provides the first set of selective inhibitors for the chaperone activity of Prx I. By identifying triptolide, celastrol, and withaferin A as covalent modulators that trigger oligomeric dissociation, the researchers have created essential tools for dissecting Prx I's complex roles in disease. Future work will focus on validating these effects in vivo and refining the selectivity of these molecules to minimize off-target interactions with other cellular proteins.
Summary updated